Patents by Inventor Andrea L. Richardson

Andrea L. Richardson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting anti-cancer response
    Patent number: 10577662
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 3, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT
    Publication number: 20190309373
    Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 10, 2019
    Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Zoltan I. Szallasi, Andrea L. Richardson, Nicolai J. Birkbak, Zhigang Wang
  • Cancer diagnosis, treatment selection and treatment
    Patent number: 10308986
    Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 4, 2019
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK, KGS
    Inventors: Zoltan I. Szallasi, Andrea L. Richardson, Nicolai J. Birkbak, Zhigang Wang
  • METHODS FOR PREDICTING ANTI-CANCER RESPONSE
    Publication number: 20170037478
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION, THE TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Methods for predicting anti-cancer response
    Patent number: 9512485
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: December 6, 2016
    Assignees: Dana-Farber Cancer Institute. Inc., The Brigham and Women's Hospital. Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • CANCER DIAGNOSIS, TREATMENT SELECTION AND TREATMENT
    Publication number: 20160122827
    Abstract: The present invention provides assays, methods and systems for selecting an effective therapy for a subset of cancer patients having cancer cells with increased expression of BML and FANCI genes and/or having copy number increase in chromosome location 15q26 in the cancer cells and for treatment of such patients with the effective therapy of cancer patients based on the personalized cancer cell expression profile.
    Type: Application
    Filed: March 13, 2014
    Publication date: May 5, 2016
    Inventors: Zoltan I. Szallasi, Andrea L. Richardson, Nicolai J. Birkbak, Zhigang Wang
  • METHOD OF DETERMINING CANCER PROGNOSIS
    Publication number: 20150292033
    Abstract: Provided is a method of predicting the prognosis of a patient with ovarian cancer by determining the total number of somatic exome mutations per genome (Nmut) and status of the BRCA1 and/or BRCA2 in the subject.
    Type: Application
    Filed: April 9, 2015
    Publication date: October 15, 2015
    Inventors: Zhigang C. Wang, James Dirk Iglehart, Andrea L. Richardson, Zoltan Szallasi, Nicolai Juul Birbak, Ursula Matulonis
  • METHODS FOR PREDICTING ANTI-CANCER RESPONSE
    Publication number: 20130281312
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Application
    Filed: August 19, 2011
    Publication date: October 24, 2013
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK, CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrea L. Richardson, Zhingang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Compositions, Kits, and Methods for Predicting Anti-Cancer Response to Anthracyclines
    Publication number: 20120052079
    Abstract: The present invention is based, in part, on the discovery that amplification of human chromosome 8q22-23 regions and over-expression of 8q22-23 genes (e.g., LAPTM4B and YWHAZ) is associated with and predictive of resistance to anthracycline-type chemotherapy. Accordingly, the invention relates to compositions, kits, and methods for predicting the response of cancer cells, e.g., breast, prostate, lung, ovarian, pancreatic, liver, and colon malignancies to anthracyclines.
    Type: Application
    Filed: August 10, 2011
    Publication date: March 1, 2012
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Andrea L. Richardson, Zhigang C. Wang